Alpha-synuclein Education and Disclosure in Individuals With Preclinical and Symptomatic Lewy Body Disease

Stanford University

Summary

The goal of the study is to assess if learning one's Lewy Body Dementia (LBD) biomarker test result impacts longitudinal psychosocial and behavioral responses and to identify factors that moderate and mediate these outcomes.

Eligibility

Age range: 40–85 years
Sex: All
Healthy volunteers: Yes

Detailed criteria

Inclusion Criteria All Participants * Able to provide 1) written, informed consent or 2) assent if a care partner can provide consent. * Access to a primary care or neurology provider for ongoing care. * 1\) willing to undergo skin biopsy or lumbar puncture for alpha-synuclein testing or 2) has access to as-yet undisclosed skin biopsy or lumbar puncture alpha-synuclein testing results. Healthy/Asymptomatic Arm * Undergoing testing for defined reason (e.g., research study) * Mini-Mental State Examination score between 26 and 30 (or MoCA between 25 and 30) * General good health (no diseases…

Interventions

Other
LBD Biomarker Education and Disclosure
In-depth interviews as well as questionnaires will be conducted with individuals who have preclinical (early stage) or symptomatic LBD.

Location

Stanford University
Stanford, California
olivialu@stanford.edu

Alpha-synuclein Education and Disclosure in Individuals With Preclinical and Symptomatic Lewy Body Disease

Summary

Eligibility

Interventions

Location

Compensation

Run this study?

Details

Conditions